Vertex Pharmaceuticals represents the convergence of drug discovery technologies. The biotechnology company uses an integrated, multidisciplinary approach -- employing biophysics, computer-based modeling, and functional genomics -- to speed up the discovery and development of new drugs. The company has two HIV drugs on the market: Agenerase and Lexiva are marketed in the US by GlaxoSmithKline. Lexiva is marketed as Telzir in the European Union. Top priorities in the company's development pipeline include drugs for hepatitis C, rheumatoid arthritis, and cystic fibrosis.